(diary, Holter) Digoxin Small series 2.3±3.1, of pts. 1.9±2.9 Unclear Propranolol mechanism of 1.5±2.3 PSVT ,0.2±0.6 (authors Verapamil speculate all 2.9±5.7 ,0.6 pts w/ AVRNT ±1.6 or oral rehydration Duration(min) therapy w/ (diary, Holter) concealed Digoxin conduction. 75±164, 47±157 Propranolol 60±112 ,1±1 Verapamil 56±148 ,1±1 Efficacy 71 Esmolol Placebo “SVT” (HR>120) VHD, AV block, Therapeutic Hypotension N/A p=NS Rapid onset of (n=36) (n=35) SSS, significant response: which occurred and short of 1986 esmolol Note: AVNRT in 18% electrolyte ≥20% in12% on action of (25) in of subjects abnormality, reduction in esmolol, 2% w/ esmolol offer precluding treatment HR, HR<100 placebo. safe, effective t of blind, w/ beta blockade, bpm, or therapy for PSVT bronchial conversion to acute asthma, ventricular NSR. treatment of r study arrhythmias requiring pts w/ PSVT. drug therapy, Therapeutic Low numbers cardiogenic shock, response to of pts w/ CHF (NYHA III-IV), esmolol AVNRT. renal or hepatic during the dysfunction, drug or initial alcohol abuse, treatment on other period (72%) blockers similar when or calcium channel esmolol was blockers w/in two given as a half-lives of study second agent entry 4 pts (6%) converted to NSR In the 80% therapeutic response lost
(diary, Holter) Digoxin 2.3±3.1, 1.9±2.9 Propranolol 1.5±2.3 ,0.2±0.6 Verapamil 2.9±5.7 ,0.6 ±1.6 Duration(min) (diary, Holter) Digoxin 75±164, 47±157 Propranolol 60±112 ,1±1 Verapamil 56±148 ,1±1 Small series of pts. Unclear mechanism of PSVT (authors speculate all pts w/ AVRNT or oral rehydration therapy w/ concealed conduction. 1986 (25) Efficacy of esmolol in of PSVT 71 study Esmolol (n=36) Placebo (n=35) “SVT” (HR>120) Note: AVNRT in 18% of subjects VHD, AV block, SSS, significant electrolyte abnormality, precluding treatment w/ beta blockade, bronchial asthma, ventricular arrhythmias requiring drug therapy, cardiogenic shock, CHF (NYHA III-IV), renal or hepatic dysfunction, drug or alcohol abuse, on other blockers or calcium channel blockers w/in two half-lives of study entry Therapeutic response: ≥20% reduction in HR, HR<100 bpm, or conversion to NSR. Therapeutic response to esmolol during the initial treatment period (72%) similar when esmolol was given as a second agent 4 pts (6%) converted to NSR In the 80% therapeutic response lost Hypotension which occurred in12% on esmolol, 2% w/ placebo. N/A p=NS Rapid onset and short of action of esmolol offer safe, effective therapy for acute treatment of pts w/ PSVT. Low numbers of pts w/ AVNRT. blind, t r
2015_SVT_Evidence_Tables_Data_Supplement.docx